Renaissance Technologies LLC lowered its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 3.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,853,799 shares of the biopharmaceutical company's stock after selling 157,723 shares during the quarter. Renaissance Technologies LLC owned approximately 6.61% of Vanda Pharmaceuticals worth $18,460,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently made changes to their positions in the company. SG Americas Securities LLC grew its holdings in shares of Vanda Pharmaceuticals by 26.8% during the 4th quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 5,459 shares during the last quarter. Wells Fargo & Company MN boosted its position in Vanda Pharmaceuticals by 28.0% during the fourth quarter. Wells Fargo & Company MN now owns 33,509 shares of the biopharmaceutical company's stock valued at $161,000 after buying an additional 7,339 shares during the period. Verition Fund Management LLC grew its stake in shares of Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company's stock valued at $189,000 after buying an additional 2,927 shares during the last quarter. Brandywine Global Investment Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 13.9% in the fourth quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company's stock worth $189,000 after buying an additional 4,820 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Vanda Pharmaceuticals by 8.8% in the 3rd quarter. Franklin Resources Inc. now owns 55,226 shares of the biopharmaceutical company's stock valued at $266,000 after acquiring an additional 4,449 shares during the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. StockNews.com assumed coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a "hold" rating on the stock. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, April 1st.
Read Our Latest Stock Report on VNDA
Vanda Pharmaceuticals Stock Up 0.2 %
Shares of Vanda Pharmaceuticals stock traded up $0.01 during trading on Tuesday, reaching $4.37. 536,831 shares of the stock were exchanged, compared to its average volume of 904,320. Vanda Pharmaceuticals Inc. has a 1 year low of $3.85 and a 1 year high of $6.75. The firm has a market cap of $254.84 million, a price-to-earnings ratio of -13.66 and a beta of 0.72. The stock's fifty day moving average is $4.62 and its 200 day moving average is $4.69.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The firm had revenue of $53.19 million for the quarter, compared to analyst estimates of $51.00 million. Equities analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.
Insider Buying and Selling at Vanda Pharmaceuticals
In related news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the stock in a transaction on Friday, February 28th. The stock was acquired at an average cost of $4.76 per share, for a total transaction of $47,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,361,730 shares of the company's stock, valued at approximately $11,241,834.80. This represents a 0.43 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders have purchased 32,000 shares of company stock valued at $151,180. 8.90% of the stock is currently owned by company insiders.
About Vanda Pharmaceuticals
(
Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Stories
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
